阿德福韦酯治疗乙型肝炎失代偿期肝硬化临床研究  

Clinical observation of Adefovir Dipivoxil on liver decompensated cirrhosis of reactive type B hepatitis

作　　者：叶鹏 史保生 

机构地区：[1]鹤壁市传染病医院,458000

出　　处：《中国实用医药》2011年第24期54-55,共2页China Practical Medicine

摘　　要：目的探讨阿德福韦酯治疗乙型肝炎失代偿期肝硬化的临床效果。方法选择本院2008年10月至2010年10月乙型肝炎失代偿期肝硬化患者78例,随机分为阿德福韦酯组和恩替卡韦组。两组在采用常规治疗的基础上,阿德福韦酯组给予阿德福韦酯,恩替卡韦组给予恩替卡韦,两组患者疗程为48周。测定两组患者治疗后HBV-DNA阴转率。结果阿德福韦酯组治疗后HBV-DNA转阴率与恩替卡韦组比较,差异无统计学意义(P>0.05)。结论与恩替卡韦相比,阿德福韦酯能够快速抑制乙型肝炎失代偿期肝硬化患者病毒复制。Objective To explore the clinical observation of Adefovir Dipivoxil on liver decompensated cirrhosis of reactive type B hepatitis. Methods 78 cases with deeompensated liver cirrhosis of reactive type B hepatitis were selected from October 2007 to August 2009, and divided into adefovir group and entecavir group. Adefovir treatment was used to adefovir group, and Entecavir was given to entecavir group on the base of routine treatment, the course was 48 weeks, the rate of HBV-DNA turn to negative was detected after treatment. Resnits the rate of HBV-DNA turn to negativet in adefovir group compared after treatment with entecavir group, there was no statistical difference （ P 〉 0. 05 ）. Conclusion Compare with Entecavir, Adefovir Dipivoril can inhabit the copy of type Bhepatitis on liver decompensated cirrhosis.

关 键 词：阿德福韦酯 乙型肝炎 肝硬化 

分 类 号：R512.62[医药卫生—内科学]